Identification of two aberrant transcripts derived from a hybridoma with amplification of functional immunoglobulin variable genes.

Cellular & Molecular Immunology
Guipeng DingBrian Cao

Abstract

Murine monoclonal antibodies (mAbs) are widely used but have limitations if administered in humans. The use of chimeric or humanized mAbs can reduce immunogenicity. The first step in producing such mAbs is to clone murine variable genes from a hybridoma, but it is possible to amplify both functional and aberrant variable genes, as they coexist in the hybridoma. During the development of a murine-human chimeric antibody, we have cloned from a hybridoma the functional heavy chain variable region (V(H)) and light chain variable region (V(L)) genes of a mAb that blocks the binding of anthrax lethal factor to protective antigen. In this study, we report the detection of two aberrant transcripts from a hybridoma produced using myeloma cell line OUR-1, the development of a method to distinguish between the functional and abundant aberrant V(L) transcripts, and the origins of these aberrant genes. The aberrant V(L) gene is derived from OUR-1 cells, while the aberrant V(H) gene might derive from antibody repertoires in B cells or from gene rearrangement in the hybridoma cells. The aberrant V(H) and V(L) genes in this study may facilitate discrimination between the functional and aberrant variable genes from hybridoma cells.

References

Apr 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·A M LawlerP J Gearhart
Oct 1, 1988·Molecular Immunology·W L CarrollS Levy
Sep 27, 1993·Journal of Immunological Methods·P J NichollsS M Andrew
May 7, 2004·Molecular Immunology·Thierry Cl LaurentXavier De Bolle
Feb 24, 2006·Cancer Immunology, Immunotherapy : CII·Ignacio AzinovicSally J DeNardo
May 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Luis R MirandaLisa A Cavacini
Jul 26, 2008·Proteomics·Johannes StadlmannFriedrich Altmann
Aug 5, 2009·Proceedings of the National Academy of Sciences of the United States of America·Zhaochun ChenRobert H Purcell
Mar 4, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bart KuenenEmile E Voest

❮ Previous
Next ❯

Citations

Jun 25, 2019·PloS One·Lena MeyerRebecca M DuBois
May 2, 2013·Biotechnology and Applied Biochemistry·Juan YangGuanxin Shen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.